India Avastin Off-Label Use: Roche Defines Responsibility
This article was originally published in Scrip
Executive Summary
Swiss multinational Roche says that it "respects" the Indian regulator's recommendations to permit off label use of its anticancer, Avastin (bevacizumab), but has made it clear that it can't be held responsible for risks associated with prescriptions for indications other than the one the product is approved for.
You may also be interested in...
Indian Avastin Biosimilar Arrives Amid Roche's Charges
Reliance Life Sciences has introduced its biosimilar version of Roche's anticancer, Avastin (bevacizumab), on the Indian market but the Swiss multinational has claimed it is unconvinced of the rigor involved in the regulatory scrutiny of the product.
Indian Avastin Biosimilar Arrives Amid Roche's Charges
Reliance Life Sciences has introduced its biosimilar version of Roche's anticancer, Avastin (bevacizumab), on the Indian market but the Swiss multinational has claimed it is unconvinced of the rigor involved in the regulatory scrutiny of the product.
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.